James Pearson
Concepts (296)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heat Stress Disorders | 7 | 2023 | 84 | 2.610 |
Why?
| | Skin Temperature | 6 | 2026 | 36 | 2.510 |
Why?
| | Lower Body Negative Pressure | 7 | 2024 | 21 | 1.990 |
Why?
| | Hemodynamics | 9 | 2026 | 1114 | 1.970 |
Why?
| | Arterial Pressure | 9 | 2026 | 130 | 1.920 |
Why?
| | Body Temperature | 6 | 2026 | 228 | 1.880 |
Why?
| | Exercise | 12 | 2026 | 2213 | 1.760 |
Why?
| | Hemorrhage | 6 | 2024 | 825 | 1.640 |
Why?
| | Cold Temperature | 4 | 2026 | 208 | 1.500 |
Why?
| | Skin | 5 | 2026 | 701 | 1.410 |
Why?
| | Body Temperature Regulation | 8 | 2026 | 106 | 1.340 |
Why?
| | Heat-Shock Response | 7 | 2023 | 78 | 1.250 |
Why?
| | Myocardium | 6 | 2026 | 948 | 1.190 |
Why?
| | Regional Blood Flow | 11 | 2026 | 507 | 1.060 |
Why?
| | Sweating | 6 | 2017 | 43 | 0.760 |
Why?
| | Fever | 6 | 2017 | 322 | 0.760 |
Why?
| | Muscle, Skeletal | 4 | 2026 | 1818 | 0.690 |
Why?
| | Skin Transplantation | 3 | 2017 | 77 | 0.690 |
Why?
| | Myocytes, Cardiac | 3 | 2026 | 544 | 0.630 |
Why?
| | Sympathetic Nervous System | 3 | 2019 | 177 | 0.630 |
Why?
| | Equilibrative Nucleoside Transport Proteins | 1 | 2019 | 1 | 0.610 |
Why?
| | Diastole | 2 | 2019 | 147 | 0.610 |
Why?
| | Hypoxia | 6 | 2016 | 1211 | 0.610 |
Why?
| | Microcirculation | 3 | 2016 | 142 | 0.610 |
Why?
| | Hot Temperature | 4 | 2017 | 396 | 0.600 |
Why?
| | Oxidative Stress | 4 | 2025 | 1369 | 0.580 |
Why?
| | Exercise Tolerance | 2 | 2018 | 289 | 0.560 |
Why?
| | Myocardial Reperfusion Injury | 1 | 2019 | 140 | 0.560 |
Why?
| | Syncope | 4 | 2023 | 48 | 0.560 |
Why?
| | Dehydration | 4 | 2013 | 59 | 0.550 |
Why?
| | Cerebrovascular Circulation | 6 | 2020 | 293 | 0.530 |
Why?
| | Burns | 4 | 2017 | 365 | 0.530 |
Why?
| | Serotonin | 1 | 2019 | 297 | 0.510 |
Why?
| | Reflex | 1 | 2017 | 69 | 0.500 |
Why?
| | Thermotolerance | 1 | 2017 | 8 | 0.500 |
Why?
| | Methacholine Chloride | 1 | 2017 | 50 | 0.500 |
Why?
| | Blood Pressure | 6 | 2026 | 1765 | 0.490 |
Why?
| | Rest | 3 | 2013 | 126 | 0.480 |
Why?
| | Prediabetic State | 1 | 2019 | 250 | 0.480 |
Why?
| | Young Adult | 16 | 2026 | 14330 | 0.440 |
Why?
| | Central Nervous System | 1 | 2017 | 278 | 0.430 |
Why?
| | Male | 43 | 2026 | 73396 | 0.430 |
Why?
| | Endothelium, Vascular | 2 | 2019 | 952 | 0.430 |
Why?
| | Leg | 3 | 2013 | 246 | 0.420 |
Why?
| | Heart | 4 | 2026 | 626 | 0.400 |
Why?
| | Drosophila melanogaster | 1 | 2015 | 237 | 0.390 |
Why?
| | Oxygen | 3 | 2015 | 997 | 0.390 |
Why?
| | Rats, Wistar | 3 | 2019 | 451 | 0.380 |
Why?
| | Synchrotrons | 4 | 2020 | 12 | 0.370 |
Why?
| | Muscle Contraction | 2 | 2010 | 438 | 0.330 |
Why?
| | Acetylcholine | 4 | 2020 | 209 | 0.320 |
Why?
| | Adult | 23 | 2026 | 41087 | 0.320 |
Why?
| | Blood Flow Velocity | 8 | 2017 | 419 | 0.310 |
Why?
| | Pulmonary Artery | 3 | 2014 | 1116 | 0.300 |
Why?
| | Coronary Artery Disease | 1 | 2016 | 751 | 0.300 |
Why?
| | Heart Rate | 4 | 2023 | 846 | 0.300 |
Why?
| | rho-Associated Kinases | 2 | 2025 | 77 | 0.300 |
Why?
| | Female | 28 | 2026 | 79499 | 0.290 |
Why?
| | Intestines | 1 | 2012 | 351 | 0.290 |
Why?
| | Inflammation | 2 | 2022 | 2919 | 0.290 |
Why?
| | Oxygen Consumption | 4 | 2018 | 721 | 0.280 |
Why?
| | Animals | 25 | 2026 | 38107 | 0.280 |
Why?
| | Myocardial Contraction | 2 | 2025 | 292 | 0.280 |
Why?
| | Aging | 3 | 2026 | 1996 | 0.260 |
Why?
| | Insulin Resistance | 1 | 2016 | 1247 | 0.260 |
Why?
| | T-Lymphocytes | 2 | 2026 | 2012 | 0.260 |
Why?
| | Time Factors | 8 | 2026 | 7109 | 0.260 |
Why?
| | Humans | 40 | 2026 | 146342 | 0.250 |
Why?
| | Homeobox Protein Nkx-2.5 | 2 | 2017 | 6 | 0.250 |
Why?
| | PPAR alpha | 1 | 2026 | 56 | 0.240 |
Why?
| | Ubiquinone | 1 | 2026 | 36 | 0.240 |
Why?
| | Angiography | 5 | 2014 | 206 | 0.240 |
Why?
| | Anaerobic Threshold | 1 | 2026 | 29 | 0.240 |
Why?
| | Hyperthermia, Induced | 3 | 2017 | 119 | 0.240 |
Why?
| | Ventricular Function, Left | 4 | 2016 | 541 | 0.230 |
Why?
| | Lactic Acid | 2 | 2026 | 295 | 0.230 |
Why?
| | Glutamate Decarboxylase | 1 | 2026 | 166 | 0.230 |
Why?
| | Mesenteric Arteries | 1 | 2025 | 17 | 0.230 |
Why?
| | Muscle Tonus | 1 | 2025 | 24 | 0.230 |
Why?
| | Creatine Kinase | 1 | 2025 | 70 | 0.230 |
Why?
| | Hydrolases | 1 | 2025 | 42 | 0.220 |
Why?
| | Sphingosine | 1 | 2025 | 46 | 0.220 |
Why?
| | Pressoreceptors | 2 | 2015 | 19 | 0.220 |
Why?
| | Carrier Proteins | 2 | 2026 | 728 | 0.220 |
Why?
| | Lysophospholipids | 1 | 2025 | 80 | 0.220 |
Why?
| | Vasodilation | 4 | 2019 | 519 | 0.210 |
Why?
| | Heart Defects, Congenital | 3 | 2018 | 923 | 0.210 |
Why?
| | Adenosine Triphosphate | 3 | 2013 | 494 | 0.210 |
Why?
| | Physical Endurance | 1 | 2026 | 278 | 0.210 |
Why?
| | Acclimatization | 2 | 2017 | 169 | 0.210 |
Why?
| | Mitochondrial Proteins | 1 | 2026 | 263 | 0.210 |
Why?
| | Cardiomyopathy, Hypertrophic | 1 | 2025 | 144 | 0.210 |
Why?
| | Disease Models, Animal | 6 | 2026 | 4580 | 0.210 |
Why?
| | Running | 1 | 2026 | 235 | 0.190 |
Why?
| | Mice, Knockout | 6 | 2026 | 3125 | 0.190 |
Why?
| | Vagus Nerve Stimulation | 2 | 2020 | 28 | 0.190 |
Why?
| | Heart Ventricles | 2 | 2019 | 762 | 0.190 |
Why?
| | Heart Failure | 2 | 2026 | 2329 | 0.180 |
Why?
| | Hydrogen Peroxide | 2 | 2025 | 337 | 0.180 |
Why?
| | Pulmonary Circulation | 3 | 2011 | 431 | 0.180 |
Why?
| | Rats | 5 | 2019 | 5586 | 0.170 |
Why?
| | Mice | 12 | 2026 | 18297 | 0.170 |
Why?
| | Interleukin-13 | 1 | 2022 | 149 | 0.170 |
Why?
| | Afferent Pathways | 1 | 2020 | 46 | 0.160 |
Why?
| | Mice, Inbred C57BL | 7 | 2026 | 6034 | 0.160 |
Why?
| | Lung | 7 | 2022 | 4122 | 0.160 |
Why?
| | Ventricular Dysfunction, Left | 2 | 2026 | 391 | 0.160 |
Why?
| | Body Surface Area | 2 | 2017 | 33 | 0.150 |
Why?
| | Stroke Volume | 2 | 2015 | 652 | 0.150 |
Why?
| | Microdialysis | 1 | 2019 | 56 | 0.150 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2026 | 1150 | 0.150 |
Why?
| | NADH, NADPH Oxidoreductases | 1 | 2019 | 23 | 0.150 |
Why?
| | Hydroxyindoleacetic Acid | 1 | 2019 | 24 | 0.150 |
Why?
| | Guanylate Cyclase | 1 | 2019 | 36 | 0.150 |
Why?
| | Connectin | 1 | 2019 | 43 | 0.150 |
Why?
| | Multienzyme Complexes | 1 | 2019 | 65 | 0.150 |
Why?
| | Positive-Pressure Respiration | 1 | 2020 | 115 | 0.150 |
Why?
| | Bicycling | 2 | 2018 | 117 | 0.150 |
Why?
| | Myosins | 1 | 2019 | 131 | 0.140 |
Why?
| | Superoxides | 1 | 2019 | 198 | 0.140 |
Why?
| | Central Venous Pressure | 2 | 2015 | 17 | 0.140 |
Why?
| | Actin Cytoskeleton | 1 | 2019 | 97 | 0.140 |
Why?
| | Middle Cerebral Artery | 3 | 2013 | 57 | 0.140 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2019 | 199 | 0.140 |
Why?
| | Mitochondria | 1 | 2025 | 997 | 0.140 |
Why?
| | Vagus Nerve | 1 | 2019 | 92 | 0.140 |
Why?
| | Quinolines | 1 | 2019 | 191 | 0.140 |
Why?
| | Random Allocation | 1 | 2018 | 366 | 0.130 |
Why?
| | Spectroscopy, Near-Infrared | 1 | 2018 | 70 | 0.130 |
Why?
| | Case-Control Studies | 2 | 2017 | 3647 | 0.130 |
Why?
| | Infusions, Subcutaneous | 1 | 2017 | 23 | 0.120 |
Why?
| | Nitric Oxide | 2 | 2019 | 883 | 0.120 |
Why?
| | Bronchopulmonary Dysplasia | 1 | 2022 | 427 | 0.120 |
Why?
| | Gases | 1 | 2016 | 45 | 0.120 |
Why?
| | Pulse Wave Analysis | 1 | 2017 | 268 | 0.120 |
Why?
| | Cytokines | 2 | 2025 | 2081 | 0.120 |
Why?
| | ERG1 Potassium Channel | 1 | 2016 | 6 | 0.120 |
Why?
| | Vasoconstriction | 5 | 2025 | 216 | 0.120 |
Why?
| | Renal Circulation | 1 | 2016 | 75 | 0.120 |
Why?
| | Point Mutation | 1 | 2017 | 232 | 0.120 |
Why?
| | Urea | 1 | 2016 | 84 | 0.120 |
Why?
| | Brain | 3 | 2020 | 2991 | 0.110 |
Why?
| | Survivors | 2 | 2017 | 526 | 0.110 |
Why?
| | Hyperventilation | 1 | 2015 | 15 | 0.110 |
Why?
| | Coronary Circulation | 1 | 2016 | 134 | 0.110 |
Why?
| | Iodine | 2 | 2014 | 26 | 0.110 |
Why?
| | Posture | 1 | 2017 | 182 | 0.110 |
Why?
| | Hyperemia | 1 | 2016 | 49 | 0.110 |
Why?
| | Respiratory Physiological Phenomena | 1 | 2015 | 34 | 0.110 |
Why?
| | Homeostasis | 2 | 2017 | 646 | 0.110 |
Why?
| | Reference Values | 1 | 2017 | 796 | 0.110 |
Why?
| | Phosphorylation | 1 | 2019 | 1724 | 0.110 |
Why?
| | Adaptation, Physiological | 2 | 2017 | 568 | 0.110 |
Why?
| | Wnt Signaling Pathway | 1 | 2017 | 211 | 0.110 |
Why?
| | Metformin | 1 | 2018 | 328 | 0.110 |
Why?
| | Metabolic Syndrome | 1 | 2018 | 364 | 0.110 |
Why?
| | Ventilation-Perfusion Ratio | 1 | 2014 | 11 | 0.110 |
Why?
| | Sweat | 1 | 2014 | 52 | 0.110 |
Why?
| | Injury Severity Score | 1 | 2017 | 572 | 0.110 |
Why?
| | Forearm | 1 | 2014 | 141 | 0.100 |
Why?
| | Arteries | 1 | 2016 | 261 | 0.100 |
Why?
| | Physical Fitness | 1 | 2015 | 209 | 0.100 |
Why?
| | Peptides | 1 | 2019 | 992 | 0.100 |
Why?
| | Adolescent | 4 | 2023 | 22557 | 0.100 |
Why?
| | Hypercapnia | 1 | 2013 | 53 | 0.100 |
Why?
| | Thermometers | 1 | 2012 | 6 | 0.090 |
Why?
| | Biological Evolution | 1 | 2016 | 471 | 0.090 |
Why?
| | Obesity | 1 | 2026 | 3131 | 0.090 |
Why?
| | Diabetes Mellitus, Type 1 | 2 | 2026 | 3930 | 0.090 |
Why?
| | Sweat Glands | 1 | 2012 | 5 | 0.090 |
Why?
| | Paper | 1 | 2012 | 9 | 0.090 |
Why?
| | Vascular Stiffness | 1 | 2017 | 488 | 0.090 |
Why?
| | Hot Flashes | 1 | 2013 | 92 | 0.090 |
Why?
| | Telemetry | 1 | 2012 | 41 | 0.090 |
Why?
| | Chronic Disease | 2 | 2016 | 1827 | 0.090 |
Why?
| | Hemoglobins | 2 | 2012 | 384 | 0.090 |
Why?
| | Animals, Newborn | 1 | 2014 | 888 | 0.080 |
Why?
| | Cardiovascular System | 1 | 2013 | 137 | 0.080 |
Why?
| | Stress, Physiological | 1 | 2014 | 450 | 0.080 |
Why?
| | Catheterization | 1 | 2012 | 179 | 0.080 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2012 | 92 | 0.080 |
Why?
| | Diagnostic Tests, Routine | 1 | 2012 | 109 | 0.080 |
Why?
| | Water-Electrolyte Balance | 1 | 2010 | 37 | 0.080 |
Why?
| | Oxyhemoglobins | 1 | 2010 | 28 | 0.080 |
Why?
| | Postmenopause | 1 | 2013 | 394 | 0.080 |
Why?
| | Nitrites | 1 | 2010 | 85 | 0.080 |
Why?
| | Cerebral Arteries | 2 | 2025 | 56 | 0.080 |
Why?
| | Epinephrine | 1 | 2010 | 160 | 0.080 |
Why?
| | Signal Transduction | 3 | 2026 | 5246 | 0.080 |
Why?
| | Norepinephrine | 1 | 2010 | 201 | 0.080 |
Why?
| | Physical Exertion | 1 | 2010 | 204 | 0.070 |
Why?
| | Hypoglycemic Agents | 1 | 2018 | 1412 | 0.070 |
Why?
| | Exercise Test | 2 | 2026 | 637 | 0.070 |
Why?
| | Kidney | 1 | 2016 | 1498 | 0.070 |
Why?
| | Disease Progression | 1 | 2016 | 2867 | 0.070 |
Why?
| | Benzofurans | 1 | 2008 | 26 | 0.070 |
Why?
| | Prognosis | 1 | 2017 | 4351 | 0.070 |
Why?
| | Antioxidants | 1 | 2011 | 544 | 0.070 |
Why?
| | Cardiac Output | 2 | 2018 | 176 | 0.060 |
Why?
| | Injections, Intradermal | 1 | 2026 | 13 | 0.060 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2008 | 138 | 0.060 |
Why?
| | Lower Extremity | 1 | 2010 | 453 | 0.060 |
Why?
| | Liver X Receptors | 1 | 2025 | 29 | 0.060 |
Why?
| | Adipose Tissue, Brown | 1 | 2026 | 60 | 0.060 |
Why?
| | Biomarkers | 3 | 2012 | 4340 | 0.060 |
Why?
| | Phenylephrine | 2 | 2015 | 74 | 0.060 |
Why?
| | Cardiomegaly | 1 | 2026 | 175 | 0.060 |
Why?
| | Middle Aged | 5 | 2025 | 36619 | 0.050 |
Why?
| | Mitochondria, Heart | 1 | 2025 | 107 | 0.050 |
Why?
| | Cognition | 1 | 2013 | 1292 | 0.050 |
Why?
| | Erythrocytes | 1 | 2010 | 750 | 0.050 |
Why?
| | Ventricular Remodeling | 1 | 2026 | 283 | 0.050 |
Why?
| | Dietary Supplements | 1 | 2008 | 587 | 0.050 |
Why?
| | Lymph Nodes | 1 | 2026 | 511 | 0.050 |
Why?
| | Autoantigens | 1 | 2026 | 426 | 0.050 |
Why?
| | Fibrosis | 1 | 2026 | 568 | 0.050 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2025 | 449 | 0.050 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2026 | 677 | 0.050 |
Why?
| | Athletes | 1 | 2026 | 432 | 0.040 |
Why?
| | Pregnancy | 3 | 2022 | 7230 | 0.040 |
Why?
| | Hypertension, Pulmonary | 2 | 2011 | 1957 | 0.040 |
Why?
| | Fluid Therapy | 2 | 2012 | 154 | 0.040 |
Why?
| | Nerve Fibers, Myelinated | 1 | 2020 | 47 | 0.040 |
Why?
| | Aged | 2 | 2017 | 26432 | 0.040 |
Why?
| | Rats, Inbred WKY | 1 | 2019 | 35 | 0.040 |
Why?
| | Vasodilator Agents | 2 | 2011 | 326 | 0.040 |
Why?
| | Analysis of Variance | 2 | 2012 | 1298 | 0.040 |
Why?
| | Perfusion | 1 | 2020 | 255 | 0.040 |
Why?
| | Rats, Sprague-Dawley | 3 | 2011 | 2537 | 0.030 |
Why?
| | Retrospective Studies | 1 | 2017 | 17438 | 0.030 |
Why?
| | Sheep | 1 | 2020 | 870 | 0.030 |
Why?
| | Infant, Premature | 1 | 2022 | 622 | 0.030 |
Why?
| | Muscles | 1 | 2018 | 330 | 0.030 |
Why?
| | Renal Veins | 1 | 2016 | 16 | 0.030 |
Why?
| | Biological Transport, Active | 1 | 2016 | 69 | 0.030 |
Why?
| | Renal Artery | 1 | 2016 | 42 | 0.030 |
Why?
| | Enzyme Inhibitors | 2 | 2011 | 823 | 0.030 |
Why?
| | Partial Pressure | 1 | 2015 | 30 | 0.030 |
Why?
| | Matched-Pair Analysis | 1 | 2015 | 38 | 0.030 |
Why?
| | Ion Channels | 1 | 2016 | 128 | 0.030 |
Why?
| | Respiration | 1 | 2015 | 208 | 0.030 |
Why?
| | Systole | 1 | 2015 | 179 | 0.030 |
Why?
| | Gene Regulatory Networks | 1 | 2017 | 319 | 0.030 |
Why?
| | Carbon Dioxide | 1 | 2015 | 228 | 0.020 |
Why?
| | Rabbits | 1 | 2014 | 651 | 0.020 |
Why?
| | Pulmonary Veins | 1 | 2014 | 110 | 0.020 |
Why?
| | Plasma Volume | 1 | 2012 | 19 | 0.020 |
Why?
| | Energy Metabolism | 1 | 2018 | 930 | 0.020 |
Why?
| | Isotonic Solutions | 1 | 2012 | 43 | 0.020 |
Why?
| | Hematocrit | 1 | 2012 | 108 | 0.020 |
Why?
| | Ultrasonography, Doppler, Transcranial | 1 | 2012 | 48 | 0.020 |
Why?
| | Glutathione Disulfide | 1 | 2011 | 30 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2017 | 2134 | 0.020 |
Why?
| | Isoprostanes | 1 | 2011 | 15 | 0.020 |
Why?
| | Echocardiography, Doppler, Pulsed | 1 | 2011 | 13 | 0.020 |
Why?
| | Texas | 1 | 2012 | 280 | 0.020 |
Why?
| | Drinking | 1 | 2011 | 44 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2012 | 432 | 0.020 |
Why?
| | Monocrotaline | 1 | 2011 | 34 | 0.020 |
Why?
| | 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 1 | 2011 | 26 | 0.020 |
Why?
| | NG-Nitroarginine Methyl Ester | 1 | 2011 | 48 | 0.020 |
Why?
| | Nitroprusside | 1 | 2011 | 70 | 0.020 |
Why?
| | Rotation | 1 | 2011 | 124 | 0.020 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2016 | 902 | 0.020 |
Why?
| | Memory, Short-Term | 1 | 2013 | 276 | 0.020 |
Why?
| | Torque | 1 | 2010 | 82 | 0.020 |
Why?
| | Elastic Modulus | 1 | 2010 | 121 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2022 | 6460 | 0.020 |
Why?
| | Glutathione | 1 | 2011 | 369 | 0.020 |
Why?
| | Superoxide Dismutase | 1 | 2011 | 307 | 0.020 |
Why?
| | Hyperoxia | 1 | 2010 | 126 | 0.020 |
Why?
| | Phenotype | 1 | 2017 | 3206 | 0.020 |
Why?
| | Cytochrome P-450 Enzyme Inhibitors | 1 | 2008 | 13 | 0.020 |
Why?
| | Enzyme Induction | 1 | 2008 | 87 | 0.020 |
Why?
| | Inhibitory Concentration 50 | 1 | 2008 | 90 | 0.020 |
Why?
| | Microsomes, Liver | 1 | 2008 | 85 | 0.020 |
Why?
| | Contrast Media | 1 | 2011 | 493 | 0.020 |
Why?
| | Propranolol | 1 | 2007 | 44 | 0.020 |
Why?
| | Biomechanical Phenomena | 1 | 2011 | 874 | 0.020 |
Why?
| | Arterioles | 1 | 2007 | 52 | 0.020 |
Why?
| | Body Weight | 1 | 2011 | 968 | 0.020 |
Why?
| | Substrate Specificity | 1 | 2008 | 389 | 0.020 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2008 | 163 | 0.020 |
Why?
| | Iopamidol | 1 | 2006 | 12 | 0.020 |
Why?
| | Drug Interactions | 1 | 2008 | 405 | 0.020 |
Why?
| | Exercise Therapy | 1 | 2011 | 488 | 0.010 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2007 | 253 | 0.010 |
Why?
| | Blood Vessels | 1 | 2006 | 164 | 0.010 |
Why?
| | Liver Diseases | 1 | 2008 | 304 | 0.010 |
Why?
| | Mutation | 1 | 2016 | 4093 | 0.010 |
Why?
| | Kinetics | 1 | 2008 | 1553 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2012 | 3416 | 0.010 |
Why?
| | Models, Molecular | 1 | 2008 | 1574 | 0.010 |
Why?
| | Protein Binding | 1 | 2008 | 2244 | 0.010 |
Why?
| | Research Design | 1 | 2007 | 1143 | 0.010 |
Why?
| | Risk Factors | 1 | 2008 | 10921 | 0.010 |
Why?
|
|
Pearson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|